Business Context and Reporting Period
This Form 8-K is filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on November 8, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The filing reports the entry into a material definitive agreement regarding its loan facility.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to debt financing:
- Loan Facility Increase: The total loan facility with Juvenescence Limited was increased from $6 million to $7 million.
- Outstanding Borrowings: The company had previously borrowed the full $6 million prior to this amendment.
- Available Capacity: An additional $1 million is available, subject to the lender's discretion and in denominations of $1 million.
Material Changes
The material change reported is the execution of Amendment No. 2 to the Loan Facility Agreement dated August 13, 2019. This amendment modifies the credit limit of the existing facility with Juvenescence Limited, expanding the maximum borrowing capacity by $1 million.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the company's future performance and plans. Management disclaims any obligation to update these statements. The document references "Risk Factors" in periodic SEC reports for details on factors that could cause actual results to differ from anticipated results. No specific operational guidance or new risk contingencies are detailed within this specific 8-K text.
Investor Verification Checklist
- Verify the full terms of Amendment No. 2 to the Loan Facility Agreement (Exhibit 10.1) for interest rates, maturity dates, and covenants.
- Confirm the company's current cash position and burn rate to assess the necessity of the additional $1 million borrowing capacity.
- Review the lender's (Juvenescence Limited) discretion criteria for releasing the additional funds.
- Check subsequent filings for any drawdowns on the increased facility.